VRCA

Insider Trades

Name	Value	Action	Price	Current Price
Manning Paul BDirector, 10 Percent Owner: $12M2.8M shares BuyNov 25, 2025 $4.24 --
Manning Paul BDirector, 10 Percent Owner: $5.8M1.4M shares BuyNov 25, 2025 $4.24 --
Manning Paul BDirector, 10 Percent Owner: $4.3M687.7k shares BuyNov 25, 2025 $6.32 --
Manning Paul BDirector, 10 Percent Owner: $2.2M343.8k shares BuyNov 25, 2025 $6.32 --
Rieger JaysonDirector, Officer: CEO And President $400k94.3k shares BuyNov 25, 2025 $4.24 --
Rosenberg Noah L.CMO $3.7k589 shares BuyNov 25, 2025 $6.32 --

News

globenewswire.comVerrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conferenceglobenewswire.comMay 28

globenewswire.comVerrica Pharmaceuticals to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQglobenewswire.comMay 13

marketbeat.comVerrica Pharmaceuticals Q1 Earnings Call Highlightsmarketbeat.comMay 12

seekingalpha.comVerrica Pharmaceuticals Inc. (VRCA) Q1 2026 Earnings Call Transcriptseekingalpha.comMay 12

zacks.comVerrica Pharmaceuticals Inc. (VRCA) Reports Q1 Loss, Tops Revenue Estimateszacks.comMay 12

Trade VRCA

About Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals Inc. is a US-based pharmaceutical company dedicated to developing and commercializing therapeutic solutions for various skin diseases. Its primary investigational compound, VP-102, has successfully completed Phase II clinical trials for molluscum contagiosum and external genital warts, and is presently in Phase II development for common warts. Additionally, the company is advancing VP-103, a cantharidin-based product candidate, designed to treat plantar warts. Verrica maintains a strategic license and collaboration agreement with Torii Pharmaceutical Co., Ltd., focusing on the development and commercialization of its product candidates, including VP-102, for molluscum contagiosum and common warts in the Japanese market. Furthermore, a separate licensing agreement with Lytix Biopharma AS allows for the development and commercialization of LTX-315 for dermatological oncology applications. Verrica Pharmaceuticals Inc. was established in 2013 and has its headquarters in West Chester, Pennsylvania.

CEO: Jayson Rieger
IPO Date: Jun 15, 2018

Market Data

Open: $6.01
High: $6.02
Low: $5.63
Volume: 26.8K
Avg Volume: 79.6K
52W High: $9.82
52W Low: $3.28

Valuation

Market Cap: $60M
Enterprise Value: $41M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-18M
Revenue: $36M
Net Income: $-18M
Cash: $30M
Debt: $1.6M

Events

EarningsAug 11

EPS est. -0.402